Association between Menopausal Hormone Therapy and Frailty: Cross-Sectional Study Using National Survey Data in Korea

• Published in: Healthcare (Basel) 2022-10, Vol.10 (11), p.2121
• Main Authors: Kim, Hyunjoo, Lee, Euni
• Format: Article
• Language: English
• Subjects: Age; Analysis; Cross-sectional studies; Endocrine therapy; estrogen replacement therapy; Estrogens; Frailty; Gender differences; Health aspects; Health surveys; hormone replacement therapy; Hormone therapy; Hormones; Hypotheses; Hysterectomy; Menopause; Oophorectomy; Patient outcomes; Physiology; Population; Postmenopausal women; Socioeconomic factors; Uterus; Womens health; women’s health
• ISSN: 2227-9032; 2227-9032
• DOI: 10.3390/healthcare10112121

Frailty is a multidimensional clinical syndrome that increases the risk of adverse health outcomes. Previous studies have reported a close link between menopause and frailty. Combined estrogen−progestin therapy (or estrogen-only therapy in women who have undergone a hysterectomy) is currently approved as a menopausal hormone therapy (MHT) to treat menopausal symptoms. Despite increasing evidence of the importance of sex hormones in the development of frailty, very few studies have investigated the association between MHT and frailty. A cross-sectional evaluation was conducted using population-based survey data known as the Korea National Health and Nutrition Examination Survey (KNHANES IV-V, 2008−2012). The KNHANES data provided variables that were used to construct a 51-item frailty index (FI). The number of study population, only including postmenopausal women, was 7823 women, and their mean age was 62.51 years (range 32−80 years). Approximately 40% of them had graduated from middle school or higher, 45% lived in metropolitan statistical areas, and 5% were recipients of the national Medical Aid. The mean age at menopause was 48.66 years (range 30−62 years). Overall, the mean FI value was 0.15, and the prevalence of MHT was 13.23%. Findings from multiple regression analysis using the inverse probability of treatment weighting showed that a treatment duration of more than 2 years and up to 5 years, age at first treatment between 50 and 59 years, and MHT initiation 3 to 6 years after menopause were all negatively associated with frailty (p < 0.05). Further studies are needed to confirm these findings using prospective data.